Product Code: TMRGL26582
The report provides revenue of the global HIV/AIDS diagnostics market for the period 2017-2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global HIV/AIDS diagnostics market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the HIV/AIDS diagnostics market.
The report delves into the competitive landscape of the global HIV/AIDS diagnostics market. Key players operating in the global HIV/AIDS diagnostics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global HIV/AIDS diagnostics market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global HIV/AIDS Diagnostics Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global HIV/AIDS Diagnostics Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projection (US$ Mn)
- 4.4.2. Market Volume/Unit Shipments Projection
- 4.5. Porter's Five Forces Analysis
5. Key Insights
- 5.1. HIV Disease Epidemiology
- 5.2. Technological Advancements
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long-term Impact)
6. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by Product
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Product, 2017-2031
- 6.3.1. Kits and Reagents
- 6.3.2. Instruments
- 6.4. Market Attractiveness Analysis, by Product
7. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by Test Type
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Test Type, 2017-2031
- 7.3.1. Nucleic Acid Tests
- 7.3.2. Rapid Tests (POC)
- 7.3.3. ELISA
- 7.3.4. Others
- 7.4. Market Attractiveness Analysis, by Test Type
8. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by End-user
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by End-user, 2017-2031
- 8.3.1. Hospitals
- 8.3.2. Diagnostic Laboratories
- 8.3.3. Academic and Research Institutes
- 8.3.4. Others
- 8.4. Market Attractiveness Analysis, by End-user
9. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region, 2017-2031
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
10. North America HIV/AIDS Diagnostics Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Market Value Forecast, by Product, 2017-2031
- 10.2.1. Kits and Reagents
- 10.2.2. Instruments
- 10.3. Market Value Forecast, by Test Type, 2017-2031
- 10.3.1. Nucleic Acid Tests
- 10.3.2. Rapid Tests (POC)
- 10.3.3. ELISA
- 10.3.4. Others
- 10.4. Market Value Forecast, by End-user, 2017-2031
- 10.4.1. Hospitals
- 10.4.2. Diagnostic Laboratories
- 10.4.3. Academic and Research Institutes
- 10.4.4. Others
- 10.5. Market Value Forecast, by Country, 2017-2031
- 10.5.1. U.S.
- 10.5.2. Canada
- 10.6. Market Attractiveness Analysis
- 10.6.1. By Product
- 10.6.2. By Test Type
- 10.6.3. By End-user
- 10.6.4. By Country
11. Europe HIV/AIDS Diagnostics Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Product, 2017-2031
- 11.2.1. Kits and Reagents
- 11.2.2. Instruments
- 11.3. Market Value Forecast, by Test Type, 2017-2031
- 11.3.1. Nucleic Acid Tests
- 11.3.2. Rapid Tests (POC)
- 11.3.3. ELISA
- 11.3.4. Others
- 11.4. Market Value Forecast, by End-user, 2017-2031
- 11.4.1. Hospitals
- 11.4.2. Diagnostic Laboratories
- 11.4.3. Academic and Research Institutes
- 11.4.4. Others
- 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Rest of Europe
- 11.6. Market Attractiveness Analysis
- 11.6.1. By Product
- 11.6.2. By Test Type
- 11.6.3. By End-user
- 11.6.4. By Country/Sub-region
12. Asia Pacific HIV/AIDS Diagnostics Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Product, 2017-2031
- 12.2.1. Kits and Reagents
- 12.2.2. Instruments
- 12.3. Market Value Forecast, by Test Type, 2017-2031
- 12.3.1. Nucleic Acid Tests
- 12.3.2. Rapid Tests (POC)
- 12.3.3. ELISA
- 12.3.4. Others
- 12.4. Market Value Forecast, by End-user, 2017-2031
- 12.4.1. Hospitals
- 12.4.2. Diagnostic Laboratories
- 12.4.3. Academic and Research Institutes
- 12.4.4. Others
- 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Product
- 12.6.2. By Test Type
- 12.6.3. By End-user
- 12.6.4. By Country/Sub-region
13. Latin America HIV/AIDS Diagnostics Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Product, 2017-2031
- 13.2.1. Kits and Reagents
- 13.2.2. Instruments
- 13.3. Market Value Forecast, by Test Type, 2017-2031
- 13.3.1. Nucleic Acid Tests
- 13.3.2. Rapid Tests (POC)
- 13.3.3. ELISA
- 13.3.4. Others
- 13.4. Market Value Forecast, by End-user, 2017-2031
- 13.4.1. Hospitals
- 13.4.2. Diagnostic Laboratories
- 13.4.3. Academic and Research Institutes
- 13.4.4. Others
- 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
- 13.6. Market Attractiveness Analysis
- 13.6.1. By Product
- 13.6.2. By Test Type
- 13.6.3. By End-user
- 13.6.4. By Country/Sub-region
14. Middle East & Africa HIV/AIDS Diagnostics Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Product, 2017-2031
- 14.2.1. Kits and Reagents
- 14.2.2. Instruments
- 14.3. Market Value Forecast, by Test Type, 2017-2031
- 14.3.1. Nucleic Acid Tests
- 14.3.2. Rapid Tests (POC)
- 14.3.3. ELISA
- 14.3.4. Others
- 14.4. Market Value Forecast, by End-user, 2017-2031
- 14.4.1. Hospitals
- 14.4.2. Diagnostic Laboratories
- 14.4.3. Academic and Research Institutes
- 14.4.4. Others
- 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
- 14.6. Market Attractiveness Analysis
- 14.6.1. By Product
- 14.6.2. By Test Type
- 14.6.3. By End-user
- 14.6.4. By Country/Sub-region
15. Competition Landscape
- 15.1. Market Player - Competition Matrix (by tier and size of companies)
- 15.2. Market Share Analysis, by Company (2021)
- 15.3. Company Profiles
- 15.3.1. Hologic, Inc
- 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.1.2. Product Portfolio
- 15.3.1.3. Financial Overview
- 15.3.1.4. SWOT Analysis
- 15.3.1.5. Strategic Overview
- 15.3.2. Abbott
- 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.2.2. Product Portfolio
- 15.3.2.3. Financial Overview
- 15.3.2.4. SWOT Analysis
- 15.3.2.5. Strategic Overview
- 15.3.3. Bio-Rad Laboratories, Inc.
- 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.3.2. Product Portfolio
- 15.3.3.3. Financial Overview
- 15.3.3.4. SWOT Analysis
- 15.3.3.5. Strategic Overview
- 15.3.4. F. Hoffmann-La Roche Ltd.
- 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.4.2. Product Portfolio
- 15.3.4.3. Financial Overview
- 15.3.4.4. SWOT Analysis
- 15.3.4.5. Strategic Overview
- 15.3.5. OraSure Technologies, Inc.
- 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.5.2. Product Portfolio
- 15.3.5.3. Financial Overview
- 15.3.5.4. SWOT Analysis
- 15.3.6. Siemens Healthcare GmbH
- 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.6.2. Product Portfolio
- 15.3.6.3. Financial Overview
- 15.3.6.4. SWOT Analysis
- 15.3.7. Chembio Diagnostics, Inc.
- 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.7.2. Product Portfolio
- 15.3.7.3. Financial Overview
- 15.3.7.4. SWOT Analysis
- 15.3.8. Danaher Corporation
- 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.8.2. Product Portfolio
- 15.3.8.3. Financial Overview
- 15.3.8.4. SWOT Analysis
- 15.3.9. Becton, Dickinson and Company
- 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.9.2. Product Portfolio
- 15.3.9.3. Financial Overview
- 15.3.9.4. SWOT Analysis